A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma

Study Summary

The purpose of this study is to evaluate the effectiveness, safety, and actual treatment status of nivolumab administered as an adjuvant treatment for participants with muscle-invasive urothelial carcinoma (MIUC), including bladder, renal pelvis, and ureteral cancer, in a Japanese real-world clinical practice.

Conditions

Muscle-invasive Urothelial Carcinoma

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment400 participants

Primary Completion—

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-04-11 04:08:14.746708+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.